

Richard J Sylvester

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7434357/publications.pdf>

Version: 2024-02-01

51
papers

13,770
citations

182225

30
h-index

286692

43
g-index

51
all docs

51
docs citations

51
times ranked

8965
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and T1c) [ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 22] | 0.9 | 559 |
| 2 | Updated European Association of Urology (EAU) Prognostic Factor Risk Groups Overestimate the Risk of Progression in Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin. <i>European Urology Oncology</i> , 2022, 5, 84-91. | 2.6 | 24 |
| 3 | Reducing the Frequency of Follow-up Cystoscopy in Low-grade pTa Non-muscle-invasive Bladder Cancer Using the ADXBLADDER Biomarker. <i>European Urology Focus</i> , 2022, 8, 1643-1649. | 1.6 | 9 |
| 4 | International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin-exposed High-risk Non-muscle-invasive Bladder Cancer. <i>European Urology</i> , 2022, 82, 34-46. | 0.9 | 30 |
| 5 | T1G1 Bladder Cancer: Prognosis for this Rare Pathological Diagnosis Within the Non-muscle-invasive Bladder Cancer Spectrum. <i>European Urology Focus</i> , 2022, . . | 1.6 | 4 |
| 6 | Comparison of the performances of the ADXBLADDER test and urinary cytology in the follow-up of non-muscle-invasive bladder cancer: a blinded prospective multicentric study. <i>BJU International</i> , 2021, 127, 198-204. | 1.3 | 21 |
| 7 | Association of patients' sex with treatment outcomes after intravesical bacillus Calmette-Guérin immunotherapy for T1G3/HG bladder cancer. <i>World Journal of Urology</i> , 2021, 39, 3337-3344. | 1.2 | 9 |
| 8 | European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. <i>European Urology</i> , 2021, 79, 480-488. | 0.9 | 198 |
| 9 | Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study. <i>European Urology Oncology</i> , 2021, 4, 182-191. | 2.6 | 54 |
| 10 | A Systematic Review of Outcome Reporting, Definition and Measurement Heterogeneity in Non-Muscle Invasive Bladder Cancer Effectiveness Trials of Adjuvant, Prophylactic Treatment After Transurethral Resection. <i>Bladder Cancer</i> , 2021, 7, 221-241. | 0.2 | 3 |
| 11 | Risk Stratification Tools and Prognostic Models in Non-muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel. <i>European Urology Focus</i> , 2020, 6, 479-489. | 1.6 | 72 |
| 12 | Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 440-448. | 0.8 | 27 |
| 13 | Diagnostic Accuracy of MCM5 for the Detection of Recurrence in Nonmuscle Invasive Bladder Cancer Followup: A Blinded, Prospective Cohort, Multicenter European Study. <i>Journal of Urology</i> , 2020, 204, 685-690. | 0.2 | 28 |
| 14 | European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and T1c) [ETQq0 0 0 rgBT /Overlock 10 Tf 50 22] | 0.9 | 936 |
| 15 | Grading of Urothelial Carcinoma and The New World Health Organisation Classification of Tumours of the Urinary System and Male Genital Organs 2016. <i>European Urology Focus</i> , 2019, 5, 457-466. | 1.6 | 112 |
| 16 | Key Steps in Conducting Systematic Reviews for Underpinning Clinical Practice Guidelines: Methodology of the European Association of Urology. <i>European Urology</i> , 2018, 73, 290-300. | 0.9 | 128 |
| 17 | A single immediate instillation of chemotherapy for non-muscle invasive bladder cancer: in all patients?. <i>Translational Andrology and Urology</i> , 2018, 7, S138-S140. | 0.6 | 0 |
| 18 | Indication for a Single Postoperative Instillation of Chemotherapy in Non-muscle-invasive Bladder Cancer: What Factors Should Be Considered?. <i>European Urology Focus</i> , 2018, 4, 525-528. | 1.6 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | How Good Are We at Predicting Outcomes in Non-Muscle Invasive Bladder Cancer?. , 2018, , 37-41. | | 0 |
| 20 | EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. European Urology, 2017, 71, 447-461. | 0.9 | 1,594 |
| 21 | Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review. European Urology, 2017, 72, 801-813. | 0.9 | 205 |
| 22 | Conflict of Evidence: Resolving Discrepancies When Findings from Randomized Controlled Trials and Meta-analyses Disagree. European Urology, 2017, 71, 811-819. | 0.9 | 23 |
| 23 | Reply to Philipp Dahm, Vikram Narayan, and Jae Hung Jung's Letter to the Editor re: Richard J. Sylvester, Steven E. Canfield, Thomas B.L. Lam, et al. Conflict of Evidence: Resolving Discrepancies When Findings from Randomized Controlled Trials and Meta-analyses Disagree. Eur Urol 2017;71:811-819. European Urology, 2017, 72, e93-e94. | 0.9 | 0 |
| 24 | Re: Maria Carmen Mir, Ithaar Derweesh, Francesco Porpiglia, Homayoun Zargar, Alexandre Mottrie, Riccardo Autorino. Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-analysis of Comparative Studies. Eur Urol. 2017;71:606-617. European Urology, 2017, 72, e59-e60. | 0.9 | 0 |
| 25 | Ensuring Consistent European-Wide Urological Care by the Use of Evidence-Based Clinical Practice Guidelines: Can We Do Better. Biomedicine Hub, 2017, 2, 1-7. | 0.4 | 1 |
| 26 | A CONSORT Effort to Improve the Reporting of Urological Randomized Controlled Trials. European Urology, 2016, 70, 1050-1051. | 0.9 | 0 |
| 27 | The impact of transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guérin. BJU International, 2016, 118, 44-52. | 1.3 | 110 |
| 28 | Reply to Stephen B. Williams and Ashish M. Kamat's Letter to the Editor re: Samantha Cambier, Richard J. Sylvester, Laurence Collette, et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage T1 Urothelial Bladder Cancer Patients Treated with 3 Years of Maintenance Bacillus Calmette-Guérin. Eur Urol 2016;69:603-609. European Urology, 2016, 69, e123-e124. | 0.9 | 11 |
| 29 | Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation? Eur Urol. In press. | 0.9 | 282 |
| 30 | Reply to Perttino Malistrassi and Bruce J. Trock's Letter to the Editor re: Richard J. Sylvester, Willem Oosterlinck, Sten Holmang, et al. Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation? Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.09.012 . | 0.9 | 0 |
| 31 | EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage T1 Urothelial Bladder Cancer Patients Treated with 3 Years of Maintenance Bacillus Calmette-Guérin. European Urology, 2016, 69, 60-69. | 0.9 | 445 |
| 32 | Reply to Stephen B. Williams, Donald L. Lam, Ashish M. Kamat's Letter to the Editor re: Richard J. Sylvester, Willem Oosterlinck, Sten Holmang, et al. Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation? Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.09.012 . | 0.9 | 0 |
| 33 | Maintenance Bacillus Calmette-Guérin Therapy: The Search for the Optimum Treatment Schedule Continues. European Urology, 2015, 68, 263-264. | 0.9 | 4 |
| 34 | European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. European Urology, 2015, 68, 868-879. | 0.9 | 804 |
| 35 | Prognostic Factors and Risk Groups in T1G3 Non-Muscle-invasive Bladder Cancer Patients Initially Treated with Bacillus Calmette-Guérin: Results of a Retrospective Multicenter Study of 2451 Patients. European Urology, 2015, 67, 74-82. | 0.9 | 190 |
| 36 | Side Effects of Bacillus Calmette-Guérin (BCG) in the Treatment of Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG. European Urology, 2014, 65, 69-76. | 0.9 | 254 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Renal Function After Nephron-sparing Surgery Versus Radical Nephrectomy: Results from EORTC Randomized Trial 30904. <i>European Urology</i> , 2014, 65, 372-377. | 0.9 | 448 |
| 38 | The Effect of Age on the Efficacy of Maintenance Bacillus Calmette-Guérin Relative to Maintenance Epirubicin in Patients with Stage Ta T1 Urothelial Bladder Cancer: Results from EORTC Genito-Urinary Group Study 30911. <i>European Urology</i> , 2014, 66, 694-701. | 0.9 | 68 |
| 39 | EAU Guidelines on Non-muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013. <i>European Urology</i> , 2013, 64, 639-653. | 0.9 | 1,053 |
| 40 | Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guérin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance. <i>European Urology</i> , 2013, 63, 462-472. | 0.9 | 382 |
| 41 | Maintenance Bacillus Calmette-Guérin Treatment of Non-muscle-invasive Bladder Cancer: A Critical Evaluation of the Evidence. <i>European Urology</i> , 2013, 64, 579-585. | 0.9 | 63 |
| 42 | Female Gender and Carcinoma In Situ in the Prostatic Urethra Are Prognostic Factors for Recurrence, Progression, and Disease-Specific Mortality in T1G3 Bladder Cancer Patients Treated With Bacillus Calmette-Guérin. <i>European Urology</i> , 2012, 62, 118-125. | 0.9 | 199 |
| 43 | A Prospective, Randomised EORTC Intergroup Phase 3 Study Comparing the Oncologic Outcome of Elective Nephron-Sparing Surgery and Radical Nephrectomy for Low-Stage Renal Cell Carcinoma. <i>European Urology</i> , 2011, 59, 543-552. | 0.9 | 910 |
| 44 | How Well Can You Actually Predict Which Non-muscle-Invasive Bladder Cancer Patients Will Progress?. <i>European Urology</i> , 2011, 60, 431-433. | 0.9 | 36 |
| 45 | Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the Bladder. <i>European Urology</i> , 2010, 57, 766-773. | 0.9 | 347 |
| 46 | The Schedule and Duration of Intravesical Chemotherapy in Patients with Non-muscle-Invasive Bladder Cancer: A Systematic Review of the Published Results of Randomized Clinical Trials. <i>European Urology</i> , 2008, 53, 709-719. | 0.9 | 162 |
| 47 | Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials. <i>European Urology</i> , 2006, 49, 466-477. | 0.9 | 2,360 |
| 48 | A SINGLE IMMEDIATE POSTOPERATIVE INSTILLATION OF CHEMOTHERAPY DECREASES THE RISK OF RECURRENCE IN PATIENTS WITH STAGE Ta T1 BLADDER CANCER: A META-ANALYSIS OF PUBLISHED RESULTS OF RANDOMIZED CLINICAL TRIALS. <i>Journal of Urology</i> , 2004, 171, 2186-2190. | 0.2 | 646 |
| 49 | Variability in the Recurrence Rate at First Follow-up Cystoscopy after TUR in Stage Ta T1 Transitional Cell Carcinoma of the Bladder: A Combined Analysis of Seven EORTC Studies. <i>European Urology</i> , 2002, 41, 523-531. | 0.9 | 563 |
| 50 | Adjuvant Chemotherapy for Superficial Transitional Cell Bladder Carcinoma: Long-term Results of a European Organization for Research and Treatment of Cancer Randomized Trial Comparing Doxorubicin, Ethoglucid and Transurethral Resection Alone. <i>Journal of Urology</i> , 1997, 158, 378-384. | 0.2 | 58 |
| 51 | A Prospective European Organization for Research and Treatment of Cancer Genitourinary Group Randomized Trial Comparing Transurethral Resection Followed by a Single Intravesical Instillation of Epirubicin or Water in Single Stage Ta, T1 Papillary Carcinoma of the Bladder. <i>Journal of Urology</i> , 1993, 149, 749-752. | 0.2 | 330 |